Cargando…

Clinical Relevance of CDH1 and CDH13 DNA-Methylation in Serum of Cervical Cancer Patients

This study was designed to investigate the DNA-methylation status of E-cadherin (CDH1) and H-cadherin (CDH13) in serum samples of cervical cancer patients and control patients with no malignant diseases and to evaluate the clinical utility of these markers. DNA-methylation status of CDH1 and CDH13 w...

Descripción completa

Detalles Bibliográficos
Autores principales: Abudukadeer, Abida, Bakry, Rania, Goebel, Georg, Mutz-Dehbalaie, Irene, Widschwendter, Andreas, Bonn, Günther K., Fiegl, Heidi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Molecular Diversity Preservation International (MDPI) 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3430238/
https://www.ncbi.nlm.nih.gov/pubmed/22942707
http://dx.doi.org/10.3390/ijms13078353
_version_ 1782241918482120704
author Abudukadeer, Abida
Bakry, Rania
Goebel, Georg
Mutz-Dehbalaie, Irene
Widschwendter, Andreas
Bonn, Günther K.
Fiegl, Heidi
author_facet Abudukadeer, Abida
Bakry, Rania
Goebel, Georg
Mutz-Dehbalaie, Irene
Widschwendter, Andreas
Bonn, Günther K.
Fiegl, Heidi
author_sort Abudukadeer, Abida
collection PubMed
description This study was designed to investigate the DNA-methylation status of E-cadherin (CDH1) and H-cadherin (CDH13) in serum samples of cervical cancer patients and control patients with no malignant diseases and to evaluate the clinical utility of these markers. DNA-methylation status of CDH1 and CDH13 was analyzed by means of MethyLight-technology in serum samples from 49 cervical cancer patients and 40 patients with diseases other than cancer. To compare this methylation analysis with another technique, we analyzed the samples with a denaturing high performance liquid chromatography (DHPLC) PCR-method. The specificity and sensitivity of CDH1 DNA-methylation measured by MethyLight was 75% and 55%, and for CDH13 DNA-methylation 95% and 10%. We identified a specificity of 92.5% and a sensitivity of only 27% for the CDH1 DHPLC-PCR analysis. Multivariate analysis showed that serum CDH1 methylation-positive patients had a 7.8-fold risk for death (95% CI: 2.2–27.7; p = 0.001) and a 92.8-fold risk for relapse (95% CI: 3.9–2207.1; p = 0.005). We concluded that the serological detection of CDH1 and CDH13 DNA-hypermethylation is not an ideal diagnostic tool due to low diagnostic specificity and sensitivity. However, it was validated that CDH1 methylation analysis in serum samples may be of potential use as a prognostic marker for cervical cancer patients.
format Online
Article
Text
id pubmed-3430238
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Molecular Diversity Preservation International (MDPI)
record_format MEDLINE/PubMed
spelling pubmed-34302382012-08-31 Clinical Relevance of CDH1 and CDH13 DNA-Methylation in Serum of Cervical Cancer Patients Abudukadeer, Abida Bakry, Rania Goebel, Georg Mutz-Dehbalaie, Irene Widschwendter, Andreas Bonn, Günther K. Fiegl, Heidi Int J Mol Sci Article This study was designed to investigate the DNA-methylation status of E-cadherin (CDH1) and H-cadherin (CDH13) in serum samples of cervical cancer patients and control patients with no malignant diseases and to evaluate the clinical utility of these markers. DNA-methylation status of CDH1 and CDH13 was analyzed by means of MethyLight-technology in serum samples from 49 cervical cancer patients and 40 patients with diseases other than cancer. To compare this methylation analysis with another technique, we analyzed the samples with a denaturing high performance liquid chromatography (DHPLC) PCR-method. The specificity and sensitivity of CDH1 DNA-methylation measured by MethyLight was 75% and 55%, and for CDH13 DNA-methylation 95% and 10%. We identified a specificity of 92.5% and a sensitivity of only 27% for the CDH1 DHPLC-PCR analysis. Multivariate analysis showed that serum CDH1 methylation-positive patients had a 7.8-fold risk for death (95% CI: 2.2–27.7; p = 0.001) and a 92.8-fold risk for relapse (95% CI: 3.9–2207.1; p = 0.005). We concluded that the serological detection of CDH1 and CDH13 DNA-hypermethylation is not an ideal diagnostic tool due to low diagnostic specificity and sensitivity. However, it was validated that CDH1 methylation analysis in serum samples may be of potential use as a prognostic marker for cervical cancer patients. Molecular Diversity Preservation International (MDPI) 2012-07-05 /pmc/articles/PMC3430238/ /pubmed/22942707 http://dx.doi.org/10.3390/ijms13078353 Text en © 2012 by the authors; licensee Molecular Diversity Preservation International, Basel, Switzerland. http://creativecommons.org/licenses/by/3.0 This article is an open-access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).
spellingShingle Article
Abudukadeer, Abida
Bakry, Rania
Goebel, Georg
Mutz-Dehbalaie, Irene
Widschwendter, Andreas
Bonn, Günther K.
Fiegl, Heidi
Clinical Relevance of CDH1 and CDH13 DNA-Methylation in Serum of Cervical Cancer Patients
title Clinical Relevance of CDH1 and CDH13 DNA-Methylation in Serum of Cervical Cancer Patients
title_full Clinical Relevance of CDH1 and CDH13 DNA-Methylation in Serum of Cervical Cancer Patients
title_fullStr Clinical Relevance of CDH1 and CDH13 DNA-Methylation in Serum of Cervical Cancer Patients
title_full_unstemmed Clinical Relevance of CDH1 and CDH13 DNA-Methylation in Serum of Cervical Cancer Patients
title_short Clinical Relevance of CDH1 and CDH13 DNA-Methylation in Serum of Cervical Cancer Patients
title_sort clinical relevance of cdh1 and cdh13 dna-methylation in serum of cervical cancer patients
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3430238/
https://www.ncbi.nlm.nih.gov/pubmed/22942707
http://dx.doi.org/10.3390/ijms13078353
work_keys_str_mv AT abudukadeerabida clinicalrelevanceofcdh1andcdh13dnamethylationinserumofcervicalcancerpatients
AT bakryrania clinicalrelevanceofcdh1andcdh13dnamethylationinserumofcervicalcancerpatients
AT goebelgeorg clinicalrelevanceofcdh1andcdh13dnamethylationinserumofcervicalcancerpatients
AT mutzdehbalaieirene clinicalrelevanceofcdh1andcdh13dnamethylationinserumofcervicalcancerpatients
AT widschwendterandreas clinicalrelevanceofcdh1andcdh13dnamethylationinserumofcervicalcancerpatients
AT bonnguntherk clinicalrelevanceofcdh1andcdh13dnamethylationinserumofcervicalcancerpatients
AT fieglheidi clinicalrelevanceofcdh1andcdh13dnamethylationinserumofcervicalcancerpatients